<scp>ISPAD</scp>
            Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes

Bock, Martin de; Codner, Ethel; Craig, Maria E.; Huynh, Tony; Maahs, David M.; Mahmud, Farid H.; Marcovecchio, Loredana; DiMeglio, Linda A.

doi:10.1111/pedi.13455

Cited by 121 publications

(84 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the moment AID systems allow us to reach glycemic goals, something which was difficult with other types of treatment. A better glycemic control with the use of advanced therapies is redefining recommended glycemic targets in patients affected by diabetes that use technology [ 92 ]. With the development of several AID systems, some of which will be approved in the near future, the joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association has created a consensus statement providing a series of recommended targeted actions with a particular focus on AID systems’ safety [ 93 ].…”

Section: Discussionmentioning

confidence: 99%

Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Bassi

Franzone

Dufour

et al. 2023

Life

View full text Add to dashboard Cite

Type 1 diabetes (T1D) patients’ lifestyle and prognosis has remarkably changed over the years, especially after the introduction of insulin pumps, in particular advanced hybrid closed loop systems (AHCL). Emerging data in literature continuously confirm the improvement of glycemic control thanks to the technological evolution taking place in this disease. As stated in previous literature, T1D patients are seen to be more satisfied thanks to the use of these devices that ameliorate not only their health but their daily life routine as well. Limited findings regarding the use of new devices in different age groups and types of patients is their major limit. This review aims to highlight the main characteristics of each Automated Insulin Delivery (AID) system available for patients affected by Type 1 Diabetes Mellitus. Our main goal was to particularly focus on these systems’ efficacy and use in different age groups and populations (i.e., children, pregnant women). Recent studies are emerging that demonstrate their efficacy and safety in younger patients and other forms of diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Bassi

Franzone

Dufour

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

“…Flash glucose monitoring and other CGM devices have the potential to improve long-term glycaemic control 13 14. Young people should be supported and encouraged to use the sensors effectively 7 13 14.…”

Section: Discussionmentioning

confidence: 99%

Flash glucose monitoring in young people with type 1 diabetes—a qualitative study of young people, parents and health professionals: ‘It makes life much easier’

et al. 2023

View full text Add to dashboard Cite

ObjectivesFlash glucose monitoring for patients with T1 diabetes avoids frequent painful finger-prick testing, thus potentially improving frequency of glucose self-monitoring. Our study aimed to explore experiences of young people using Freestyle Libre sensors and their parents, and to identify benefits and challenges to National Health Service (NHS) staff of its adoption in their care provision.ParticipantsYoung people with T1 diabetes, their parents and healthcare professionals were interviewed between February and December 2021. Participants were recruited via social media and through NHS diabetes clinic staff.DesignSemistructured interviews were conducted online and analysed using thematic methods. Staff themes were mapped onto normalisation process theory (NPT) constructs.ResultsThirty-four participants were interviewed: 10 young people, 14 parents and 10 healthcare professionals. Young people reported that life was much easier since changing to flash glucose monitoring, increasing confidence and independence to manage their condition. Parents’ quality of life improved and they appreciated access to real-time data. Using the NPT concepts to understand how technology was integrated into routine care proved useful; health professionals were very enthusiastic about flash glucose monitoring and coped with the extra data load to facilitate more tailored patient support within and between clinic visits.ConclusionThis technology empowers young people and their parents to understand their diabetes adherence more completely; to feel more confident about adjusting their own care between clinic appointments; and provides an improved interactive experience in clinic. Healthcare teams appear committed to delivering improving technologies, acknowledging the challenge for them to assimilate new information required to provide expert advice.

show abstract

“…The goal of the initial treatment was to achieve an HbA1c level of less than 7.0% (53 mmol/mol). In some cases, a target of less than 6.5% (48 mmol/mol) is recommended without the occurrence of hypoglycemic events (27,28). If the HbA1c target is not achieved and the HbA1c level is 6.5-9.0% (48-74 mmol/mol), metformin monotherapy should be continued with a maximum dose of 2 g/d within 4 mo, in addition to a second drug (25,29).…”

Section: Subsequent Treatmentmentioning

confidence: 99%

Treatment strategy for children and adolescents with type 2 diabetes-based on ISPAD Clinical Practice Consensus Guidelines 2022

Urakami

2023

Clin Pediatr Endocrinol

View full text Add to dashboard Cite

show abstract

ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes

Cited by 121 publications

References 60 publications

Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Flash glucose monitoring in young people with type 1 diabetes—a qualitative study of young people, parents and health professionals: ‘It makes life much easier’

Treatment strategy for children and adolescents with type 2 diabetes-based on ISPAD Clinical Practice Consensus Guidelines 2022

Contact Info

Product

Resources

About